CClinicalTrials.gg
CompletedNCT02430038Updated Oct 8, 2024Results posted

Transperineal Ultrasound to Assess the Progress of Labour

An observational study in Placenta Praevia and Vaginismus, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Imperial College London · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
584
Ages
18 Years to 44 Years
Sex
Female
01

Study summary

This is a prospective observational study of transperineal ultrasound between 24-42 weeks gestation and a prospective longitudinal observational study in all term (37-42 weeks) labouring women.

Read the detailed description

This is a prospective observational study of transperineal ultrasound between 24-42 weeks gestation and a prospective longitudinal observational study in all term (37-42 weeks) labouring women.

AIMS:

This study aims to firstly assess the effectiveness and acceptability of transperineal ultrasound in women presenting between 24 and 42 weeks gestation in comparison with digital vaginal examination (VE). Secondly, in all term (37-42 weeks) labouring women, investigators aim to create an ultrasound based labour record, "a sonopartogram" and from this develop a predictive model for the outcome of labour.

02

Conditions studied

  • Placenta Praevia
  • Vaginismus

Keywords

  • transperineal ultrasound
  • labour
  • sonopartogram
  • prediction model
03

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Group 1: acceptability and feasibility group

Group 2: predictive model group

Inclusion criteria

  • Gestation 24-42 completed weeks at study entry
  • Aged 18-44
  • Cephalic
  • Singleton pregnancies
  • Nulliparous
  • Multiparous (excluded for the term predictive model group)
  • Multiple pregnancies (excluded for the term predictive model group)
  • Established (Active) phase of labour (included for the term predictive model group) o Clinician opinion that patient is in the established phase of labour according to the current NICE guidelines

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years.
  • Imminent iatrogenic intention to deliver
  • Life threatening maternal or fetal compromise needing immediate medical attention and/or delivery
  • Women who in the opinion of the researcher by virtue of language or learning impairment would be unable to give fully informed consent to the study.
  • Miscarriage
  • Intra-uterine death
  • Previous cervical surgery eg. cone biopsy, cervical cerclage. Note- Single LLETZ is not excluded.
  • Non-cephalic presentations
  • Multiple pregnancies (for the term predictive model group)
  • Multiparous patients (for the term predictive model group)
  • Not in established labour (for the term predictive model group)
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
584 participants (actual)
Patient registry
No

Groups and cohorts

  • Acceptability

    To assess acceptability of intervention. Some patients from this group also participated in the other groups.

  • Feasibility

    Is it possible for ultrasound to measure labour parameters, where vaginal examinations are best avoided e.g. vaginismus or contraindicated (PPROM) with controls. Some patients from this group also participated in the other groups.

  • Predictive Model

    Nulliparous term labouring women with cephalic presentation. Some patients from this group also participated in the other groups.

05

What researchers measure

Primary outcomes

  1. Caesarean Delivery

    Number of Caesarean deliveries in the prediction group

    Time frame: 24 months

  2. Acceptability of Intrapartum Ultrasound

    Acceptability of transabdominal and transperineal ultrasound to pregnant and labouring women. Use of modified W-DEQ questionnaires pre and post assessment. We recorded the number of women who completed both questionnaires.

    Time frame: 24 months

  3. Feasibility of Ultrasound Labour Parameters

    The outcome was the number of women who had all labour parameters measured by ultrasound.

    Time frame: 24 months

06

Results

Posted Oct 8, 2024

Participant flow

This study aimed to firstly assess the feasibilty and acceptability of transperineal ultrasound in women presenting between 24 and 42 weeks gestation in comparison with digital vaginal examination (VE). Secondly, in all term (37-42 weeks) labouring women, we aim to create an ultrasound based labour record, "a sonopartogram" and from this develop a predictive model for the outcome of labour.

Participant flow — Overall Study
MilestoneAcceptabilityFeasibilityPredictive Model
Started119195270
Minimum recruitment42100270
Completed119195269
Not completed001

Outcome measures

PrimaryCaesarean Delivery

Number of Caesarean deliveries in the prediction group

Time frame:
24 months
Reported as:
Count of participants · Participants
Caesarean Delivery
ParticipantsAcceptabilityFeasibilityPredictive Model
Caesarean Delivery——79
PrimaryAcceptability of Intrapartum Ultrasound

Acceptability of transabdominal and transperineal ultrasound to pregnant and labouring women. Use of modified W-DEQ questionnaires pre and post assessment. We recorded the number of women who completed both questionnaires.

Time frame:
24 months
Reported as:
Count of participants · Participants
Acceptability of Intrapartum Ultrasound
ParticipantsAcceptabilityFeasibilityPredictive Model
Acceptability of Intrapartum Ultrasound10400
PrimaryFeasibility of Ultrasound Labour Parameters

The outcome was the number of women who had all labour parameters measured by ultrasound.

Time frame:
24 months
Reported as:
Count of participants · Participants
Feasibility of Ultrasound Labour Parameters
ParticipantsAcceptabilityFeasibilityPredictive Model
Feasibility of Ultrasound Labour Parameters01680

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acceptability0/119 (0%)0/119 (0%)0/119 (0%)
Feasibility of the Study0/195 (0%)0/195 (0%)0/195 (0%)
Predictive Model0/270 (0%)0/270 (0%)0/270 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Acceptability and FeasibiltyFeasibilityPredictive ModelTotal
Median31.2 ± 5.331 ± 4.831.0 ± 5.131 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)Acceptability and FeasibiltyFeasibilityPredictive ModelTotal
Female119195270584
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Acceptability and FeasibiltyFeasibilityPredictive ModelTotal
Hispanic or Latino0000
Not Hispanic or Latino119195270584
Unknown or Not Reported0000
Regional analgesia
Regional analgesia(Participants)Acceptability and FeasibiltyFeasibilityPredictive ModelTotal
Count of participants95178211484
07

Study locations

1 site
  • Imperial College Healthcare NHS Trust
    London, W12 0HS, United Kingdom
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Feb 19, 2015

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT02430038
Lead sponsor
Imperial College London
Collaborators
Imperial College Healthcare NHS Trust, KU Leuven, Norwegian University of Science and Technology, British Medical Association
Responsible party
Sponsor
First posted
Apr 29, 2015
Start date
Apr 2015
Primary completion
Jan 19, 2018
Completion
Jan 19, 2018
Results posted
Oct 8, 2024
Last update
Oct 8, 2024

Study contacts

Christoph Lees, MD MRCOG
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion